Intellia Therapeutics ↗
Biotechnology: In Vitro & In Vivo Diagnostic Substances company
Key Metrics of Intellia Therapeutics
Revenue$36.3M▼ 30.4% YoYFY 2023
Operating income−$515M▼ 12.5% YoY
Net profit−$481M▼ 1.5% YoY
Shareholders' equity$1.1B
Market cap$1.9BNTLA · $13.23
Competitors10identified
About Intellia Therapeutics
Sectors
Company details
- Website
- intelliatx.com
- Founded
- 2016
- Listed
- Nasdaq: NTLA (since 2016)
Operational Areas of Intellia Therapeutics
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameIntellia Therapeutics Inc.
TickerNTLA
ExchangeNasdaq
CountryUnited States
SEC CIK0001652130
Listed since2016
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Websitehttp://intelliatx.com
US market & SEC filings
NTLA · Nasdaq · SEC CIK 0001652130
Last price · 30 Oct 2026
$13.23
−0.68%
Market cap$1.9B
P/E—On FY 2023 diluted EPS
Volume4,703,882
SectorHealth CareBiotechnology: In Vitro & In Vivo Diagnostic Substances
Country · IPOUnited StatesListed 2016
NTLA share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeCambridge
GSTIN—
Email—
Websitehttp://intelliatx.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Intellia Therapeutics
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
biotechnology, Q58293258
Filings
No filings on record yet.